Pipeline
Virogin is dedicated to bringing next-generation immuno-oncology therapeutics to the clinic through our robust pipeline.
Oncolytic Virus (Attenuated & Non-attenuated Viral Backbone）
Backbone
ID#
Indications
PHASE
Discovery
IND-Enabling
Phase I
Phase II
Phase III
Commercial
Virogin rights
Attenuated
ID#:
VG161*
(I.T)
Indications:
HCC, ICC, etc.
HCC, ICC, etc.
Phase:
Virogin Rights:
Worldwide excluding Greater China
Transcription & Translation
Dual Regulation (TTDR)
ID#:
VG201
(I.T)
Indications:
Solid Tumors
Solid Tumors
Phase:
Virogin Rights:
Worldwide
ID#:
VG201
(I.V)
Indications:
Solid Tumors
Solid Tumors
Phase:
Virogin Rights:
Worldwide
ID#:
VG203
Indications:
Solid Tumors
Solid Tumors
Phase:
Virogin Rights:
Worldwide
ID#:
VG302
Indications:
Solid Tumors
Solid Tumors
Phase:
Virogin Rights:
Worldwide
mRNA Vaccines and Therapeutics (Conventional mRNA & Self-amplifying RNA）
ID#
Potential Indications
PHASE
Discovery
IND-Enabling
Phase I
Phase II
Phase III
Commercial
Virogin rights
ID#:
Monkeypox mRNA vaccine
Potential Indications:
Monkeypox
Monkeypox
Phase
Virogin Rights:
Worldwide
ID#:
HPV (Human papilloma virus)
Potential Indications:
HPV16- associated skin lesions, HPV16+ cancer, HSIL
HPV16- associated skin lesions, HPV16+ cancer, HSIL
Phase
Virogin Rights:
Worldwide
ID#:
HER2 mRNA vaccine
Potential Indications:
HER2+ tumors
HER2+ tumors
Phase
Virogin Rights:
Worldwide
ID#:
EBV (Epstein-Barr virus) mRNA vaccine
Potential Indications:
EBV+ tumors
EBV+ tumors
Phase
Virogin Rights:
Worldwide
*VG161 to be developed for the Greater China market in partnership with CNBG, a Sinopharm subsidiary (Virogin Biotech retains worldwide rights excluding Greater China);
i.t= intratumoral; i.v= intravenous
